Maybe - but i’d find it very strange if Hayes was involved at all after resigning. Granted i give that Hayes expererience only really rests in discovery/preclinical. But has he left them with something that others want to outlicense ? I guess that comes in if they can find a deal ? It looks a bit premature and comes as the 4th big pharma guy they’ve had trying to lead them over the past decade. Time will tell .....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |